1. Home
  2. VIGL vs FSHP Comparison

VIGL vs FSHP Comparison

Compare VIGL & FSHP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • FSHP
  • Stock Information
  • Founded
  • VIGL 2020
  • FSHP 2018
  • Country
  • VIGL United States
  • FSHP United States
  • Employees
  • VIGL N/A
  • FSHP N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • FSHP
  • Sector
  • VIGL Health Care
  • FSHP
  • Exchange
  • VIGL Nasdaq
  • FSHP NYSE
  • Market Cap
  • VIGL 89.3M
  • FSHP 90.7M
  • IPO Year
  • VIGL 2022
  • FSHP 2024
  • Fundamental
  • Price
  • VIGL $2.11
  • FSHP $10.33
  • Analyst Decision
  • VIGL Strong Buy
  • FSHP
  • Analyst Count
  • VIGL 5
  • FSHP 0
  • Target Price
  • VIGL $21.00
  • FSHP N/A
  • AVG Volume (30 Days)
  • VIGL 227.2K
  • FSHP 3.5K
  • Earning Date
  • VIGL 03-13-2025
  • FSHP 01-01-0001
  • Dividend Yield
  • VIGL N/A
  • FSHP N/A
  • EPS Growth
  • VIGL N/A
  • FSHP N/A
  • EPS
  • VIGL N/A
  • FSHP 0.17
  • Revenue
  • VIGL N/A
  • FSHP N/A
  • Revenue This Year
  • VIGL N/A
  • FSHP N/A
  • Revenue Next Year
  • VIGL N/A
  • FSHP N/A
  • P/E Ratio
  • VIGL N/A
  • FSHP $62.48
  • Revenue Growth
  • VIGL N/A
  • FSHP N/A
  • 52 Week Low
  • VIGL $1.49
  • FSHP $9.99
  • 52 Week High
  • VIGL $6.06
  • FSHP $10.33
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 38.32
  • FSHP N/A
  • Support Level
  • VIGL $2.15
  • FSHP N/A
  • Resistance Level
  • VIGL $2.55
  • FSHP N/A
  • Average True Range (ATR)
  • VIGL 0.23
  • FSHP 0.00
  • MACD
  • VIGL -0.05
  • FSHP 0.00
  • Stochastic Oscillator
  • VIGL 4.72
  • FSHP 0.00

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About FSHP FLAG SHIP ACQUISITION CORPORATION

Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: